Background: The estrogen receptor (ER) can change expression between primary tumor (PT) and distant metastasis (DM) in breast cancer. A tissue biopsy reflects a momentary state at one location, whereas circulating tumor cells (CTCs) reflect real-time tumor progression. We evaluated ER-status during tumor progression from PT to DM and CTCs, and related the ER-status of CTCs to prognosis. Methods: In a study of metastatic breast cancer, blood was collected at different timepoints. After CellSearch® enrichment, CTCs were captured on DropMount slides and evaluated for ER expression at baseline (BL) and after 1 and 3 months of therapy. Comparison of the ER-status of PT, DM, and CTCs at different timepoints was performed using the McNemar test. T...
There is increasing interest in circulating tumor cells (CTCs) due to their purported role in breast...
AbstractBACKGROUND: Preclinical and clinical studies have reported that human epidermal growth facto...
BACKGROUND: Changes in the receptor profile of primary breast cancers to their metastases (receptor ...
<div><p>Background</p><p>Endocrine treatment is the most preferable systemic treatment in metastatic...
Background/Aim: Knowing the molecular footprint of tumors is a precondition for personalized medicin...
Background: Recent studies have shown that the expression status of hormone receptors and human epid...
BACKGROUND: Preclinical and clinical studies have reported that human epidermal growth factor recept...
After five years of endocrine therapy, patients with ER+ (estrogen receptor positive) breast cancer ...
After five years of endocrine therapy, patients with ER+ (estrogen receptor positive) breast cancer ...
BACKGROUND: We evaluated both estrogen receptor (ER) and human epidermal growth factor receptor 2 (H...
AbstractBACKGROUND: We evaluated both estrogen receptor (ER) and human epidermal growth factor recep...
AbstractHormone therapy and anti-ErbB2 therapies are prescribed according to the hormone receptor [e...
Abstract Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). The CTC-end...
Background: In metastatic breast cancer, hormone and/or human epidermal growth factor receptor 2 (HE...
Background: In metastatic breast cancer, hormone and/or human epidermal growth factor receptor 2 (HE...
There is increasing interest in circulating tumor cells (CTCs) due to their purported role in breast...
AbstractBACKGROUND: Preclinical and clinical studies have reported that human epidermal growth facto...
BACKGROUND: Changes in the receptor profile of primary breast cancers to their metastases (receptor ...
<div><p>Background</p><p>Endocrine treatment is the most preferable systemic treatment in metastatic...
Background/Aim: Knowing the molecular footprint of tumors is a precondition for personalized medicin...
Background: Recent studies have shown that the expression status of hormone receptors and human epid...
BACKGROUND: Preclinical and clinical studies have reported that human epidermal growth factor recept...
After five years of endocrine therapy, patients with ER+ (estrogen receptor positive) breast cancer ...
After five years of endocrine therapy, patients with ER+ (estrogen receptor positive) breast cancer ...
BACKGROUND: We evaluated both estrogen receptor (ER) and human epidermal growth factor receptor 2 (H...
AbstractBACKGROUND: We evaluated both estrogen receptor (ER) and human epidermal growth factor recep...
AbstractHormone therapy and anti-ErbB2 therapies are prescribed according to the hormone receptor [e...
Abstract Circulating tumor cells (CTC) are prognostic in metastatic breast cancer (MBC). The CTC-end...
Background: In metastatic breast cancer, hormone and/or human epidermal growth factor receptor 2 (HE...
Background: In metastatic breast cancer, hormone and/or human epidermal growth factor receptor 2 (HE...
There is increasing interest in circulating tumor cells (CTCs) due to their purported role in breast...
AbstractBACKGROUND: Preclinical and clinical studies have reported that human epidermal growth facto...
BACKGROUND: Changes in the receptor profile of primary breast cancers to their metastases (receptor ...